ClinicalTrials.gg
RecruitingNCT06938880Updated Jan 5, 2026

Study of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid Tumors

A Phase 1/2 interventional study of ZGGS18 for Injection and ZG005 for Injection in Advanced Solid Tumor, sponsored by Suzhou Zelgen Biopharmaceuticals Co.,Ltd. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-01-05.

Sponsored by Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started May 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This trial is designed to assess the tolerability, safety, pharmacokinetic profile, and preliminary efficacy of the combination of ZGGS18 and ZG005 in patients with advanced solid tumors, including advanced cervical cancer, hepatocellular carcinoma, neuroendocrine cancer, and lung cancer.

02

Conditions studied

  • Advanced Solid Tumor
03

In context

Lead sponsor

Suzhou Zelgen Biopharmaceuticals Co.,Ltd is the lead sponsor of 83 studies on the registry; 29 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Fully understand this study and voluntarily sign the ICF.
  • Age 18-75 years, no gender restriction.
  • Patients with advanced solid tumors who have failed standard treatment or are intolerant to standard treatment, as confirmed by histopathology or cytology.

Exclusion criteria

Exclusion Criteria:

  • Medical history, CT scan, or MRI indicates the presence of .
  • Other within 5 years.
  • Any other reason deeming the participant unsuitable for the study, as judged by the investigator.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Phase 1 Dose Escalation

    ZG005 will be given 10mg/kg or 20mg/kg or other dose every three weeks and ZGGS18 will be given 10 mg/kg every three weeks

    Biological: ZGGS18 for Injection · Biological: ZG005 for Injection

  • Experimental
    Phase 2 Dose Expansion

    ZG005 will be given RP2D every three weeks and ZGGS18 will be given 10 mg/kg every three weeks

    Biological: ZGGS18 for Injection · Biological: ZG005 for Injection

Interventions

  • BiologicalZGGS18 for Injection

    Intravenous infusion

    Also known as: ZGGS18

  • Intravenous infusion

    Also known as: ZG005

06

What researchers measure

Primary outcomes

  1. Dose limited toxicity(DLT)

    Incidence and severity of DLT events

    Time frame: up to 21 days

  2. Adverse Event (AE)

    Abnormal changes in clinical symptoms, vital signs, physical examination, laboratory tests, electrocardiograph and other examinations.

    Time frame: Up to 2 years

  3. Maximum tolerated dose(MTD)

    Time frame: Up to 1 years

  4. Recommended phase II dose(RP2D)

    Time frame: Up to 1 years

Secondary outcomes

  1. Objective response rate (ORR)

    Objective Response Rate as Assessed by Investigator according to RECIST v1.1

    Time frame: Up to 2 years

  2. Immunogenicity

    Incidence of antidrug antibodies (ADA)

    Time frame: Up to 2 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2025 (actual). Primary completion is estimated for May 2027, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2025
First posted
Apr 22, 2025
StartActual
May 20, 2025
Primary completionEst.
May 2027
CompletionEst.
Apr 2028
Last update
Jan 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06938880
Responsible party
Sponsor
First posted
Apr 22, 2025
Start date
May 20, 2025
Primary completion
May 2027 (estimated)
Completion
Apr 2028 (estimated)
Last update
Jan 5, 2026

Study contacts

Siqi Jia
Contact
jiasy@zelgen.com
+86-0512-57018310
Jason Wu
study chair · Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nilvanstomig

Start the discussion